Literature DB >> 12700677

Antisense knockdown of the Shaker-like Kv1.1 gene abolishes the central stimulatory effects of amphetamines in mice and rats.

Carla Ghelardini1, Alessandro Quattrone, Nicoletta Galeotti, Silvia Livi, Grazia Banchelli, Laura Raimondi, Renato Pirisino.   

Abstract

Amphetamine (AMPH) is an indirect sympathomimetic compound classified as a substrate-type releaser that distinguishes it from other stimulants that act as uptake 1 blockers, such as cocaine (COC). In mammals, AMPH elicits central stimulation, hypermotility, anorexia, analgesia and analeptic activity, mainly through the increase of extracellular brain dopamine (DA). The inversion of vesicular transporters and/or intravesicular alkalinization is assumed to have a role in AMPH-induced exocytosis. However, the action mechanism of this compound has not yet been completely clarified. Recent evidence on the action of AMPHs indicates potassium channel-blocking properties in peripheral tissues. We investigated the possible involvement of a Shaker-like Kv1.1 channel subtype in the central effects of AMPH, using an antisense oligodeoxyribonucleotide (aODN) that specifically and reversibly inhibits the expression of these channels in the brain. The effect of aODN pretreatments was studied by evaluating the modification of behavioral effects induced in mice through the intracerebroventricular administration of AMPH, COC, or other compounds. The aODN in mice almost completely blocked the stimulatory effects of AMPH and other releasers but was ineffective in reducing the central activity of COC. In aODN-pretreated rats a strong reduction of the AMPH, but not of the COC-stimulated DA efflux from nucleus accumbens was observed. Our results suggest that the stimulant effects of AMPH and chemically related compounds, but not COC, require the presence of functionally active Kv1.1 channels in the brain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12700677     DOI: 10.1038/sj.npp.1300162

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  7 in total

Review 1.  Dopamine D2 autoreceptor interactome: Targeting the receptor complex as a strategy for treatment of substance use disorder.

Authors:  Rong Chen; Mark J Ferris; Shiyu Wang
Journal:  Pharmacol Ther       Date:  2020-05-27       Impact factor: 12.310

2.  4-methyl benzylamine stimulates food consumption and counteracts the hypophagic effects of amphetamine acting on brain Shaker-like Kv1.1 channels.

Authors:  Renato Pirisino; Nicoletta Galeotti; Silvia Livi; Laura Raimondi; Carla Ghelardini
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

3.  Methylamine-dependent release of nitric oxide and dopamine in the CNS modulates food intake in fasting rats.

Authors:  L Raimondi; C Alfarano; A Pacini; S Livi; C Ghelardini; G DeSiena; R Pirisino
Journal:  Br J Pharmacol       Date:  2007-03-05       Impact factor: 8.739

4.  Methylamine, but not ammonia, is hypophagic in mouse by interaction with brain Kv1.6 channel subtype.

Authors:  Renato Pirisino; Carla Ghelardini; Alessandra Pacini; Nicoletta Galeotti; Laura Raimondi
Journal:  Br J Pharmacol       Date:  2004-04-20       Impact factor: 8.739

Review 5.  Dopamine and aging: intersecting facets.

Authors:  C David Rollo
Journal:  Neurochem Res       Date:  2008-10-08       Impact factor: 3.996

6.  Usp46 is a quantitative trait gene regulating mouse immobile behavior in the tail suspension and forced swimming tests.

Authors:  Shigeru Tomida; Takayoshi Mamiya; Hirotake Sakamaki; Masami Miura; Toshihiko Aosaki; Masao Masuda; Minae Niwa; Tsutomu Kameyama; Junya Kobayashi; Yuka Iwaki; Saki Imai; Akira Ishikawa; Kuniya Abe; Takashi Yoshimura; Toshitaka Nabeshima; Shizufumi Ebihara
Journal:  Nat Genet       Date:  2009-05-24       Impact factor: 38.330

Review 7.  The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens.

Authors:  Clinton E Canal; Kevin S Murnane
Journal:  J Psychopharmacol       Date:  2016-11-15       Impact factor: 4.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.